Tosymra® is a prescription medicine used to treat acute migraine with or without aura in adults.

Tosymra is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines. Tosymra is not used to treat cluster headaches.

Tosymra is not used to prevent or decrease the number of migraines you have. It is not known if Tosymra is safe and effective in children under 18 years of age.

Migraine pain relief in as little as 10 minutes

Some patients experience migraine pain relief in as little as 10 minutes with just one spray (13% vs. 5% for placebo).*1-3

Efficacy of Tosymra is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.

*Time to onset and degree of pain relief varies by patient.

Learn More

Tosymra for free†

Commercially insured patients pay $0† per prescription, regardless of coverage, with the Access Pathways® Program; free home delivery available through Blink Pharmacy Plus.

†Restrictions apply. Platinum Pass® savings card or filling prescription through Blink Pharmacy Plus required. Maximum of eight single-dose nasal spray units per month. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.

Savings Program

Tosymra is simple to use

Watch the Instructions for Use video to learn how to use Tosymra.

Please see Important Safety Information; full Prescribing Information, including Patient Information; and Instructions for Use.

References

  1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.